GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Other Gross PPE

Biocure Technology (XCNQ:CURE) Other Gross PPE : C$0.00 Mil (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Other Gross PPE?

Biocure Technology's Other Gross PPE for the quarter that ended in Mar. 2025 was C$0.00 Mil.


Biocure Technology Other Gross PPE Historical Data

The historical data trend for Biocure Technology's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Other Gross PPE Chart

Biocure Technology Annual Data
Trend Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.56 - - -

Biocure Technology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biocure Technology Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Biocure Technology Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a biopharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Executives
Konstantin Lichtenwald Director, Senior Officer

Biocure Technology Headlines